Monopar Therapeutics Inc
NASDAQ:MNPR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Monopar Therapeutics Inc
Monopar Therapeutics Inc
Total Liabilities
Monopar Therapeutics Inc
Total Liabilities Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Liabilities Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
Total Liabilities
$1.4m
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$140.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$38.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$88B
|
CAGR 3-Years
18%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$5.4B
|
CAGR 3-Years
20%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$7.4B
|
CAGR 3-Years
8%
|
CAGR 5-Years
17%
|
CAGR 10-Years
22%
|
See Also
What is Monopar Therapeutics Inc's Total Liabilities?
Total Liabilities
1.4m
USD
Based on the financial report for Mar 31, 2024, Monopar Therapeutics Inc's Total Liabilities amounts to 1.4m USD.
What is Monopar Therapeutics Inc's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
20%
Over the last year, the Total Liabilities growth was -50%. The average annual Total Liabilities growth rates for Monopar Therapeutics Inc have been 21% over the past three years , 20% over the past five years .
You don't have any saved screeners yet
